Q4 2024 Earnings Call Transcript March 11, 2025 MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.1004, ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Vertex's products are known as cystic fibrosis transmembrane ... The company's blood disorders treatment -- Casgevy -- also is a multibillion-dollar opportunity, according to Vertex.

AWS’s framework will speed up the analysis of ElevateBio’s large protein datasets, hinting at promising drug candidates.

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in ...

Remarkable technological advancements have shaped the history of medicine for over 150 years. Historical breakthroughs have ...

The Medicines and Healthcare products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy ...

Transformational drugs rarely emerge from a targeted, application-driven approach. Rather, they arise from deep scientific inquiry over many years, an approach that only robust, early-stage funding ...

Crispr Therapeutics is the only biotech of the three that has a product on the market. Along with partner Vertex Pharmaceuticals, it has won regulatory approval for Casgevy, a revolutionary ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product. We recently compiled a list of the Cathie Wood’s Stock ...

The product has been launched in 35 countries around ... as well as Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia – both autologous cell therapies that seek to address the ...